

Selected Clonal Traits for NK cell Therapy



PRINCIPAL INVESTIGATORS/COLLABORATORS

Timo Rückert

Charité Universitätsmedizin Berlin

ATMP

Methods/Plattform

SUMMARY

NK cell therapies are still hindered by poor in vivo persistence and limited proliferative capacity, which restrict their long-term efficacy.

The team identified somatic mutations that can boost NK cell efficacy.

During the funding period they aim to optimize and validate a gene editing strategy to introduce the identified mutations in NK cells for NK cell therapy.

PROJECT GOALS

- Develop method to equip NK cell therapeutics with enhanced fitness.
- IP protection.

LONG-TERM GOALS

- License IP to biotech or pharma companies.
- Co-development of enhanced NK cell therapy platform suitable for commercialization via start-up.